Table 1 Transcriptomic and proteomic classifiers of triple negative breast cancer
TNBC Classifier | Year | Number of TNBC cases | Subtypes | Biological level information | Key clinical findings |
|---|---|---|---|---|---|
Transcriptomic profiling | |||||
Lehmann et al.[4] Lehmann et al. [57] | 2011 Refined in 2016 | 587 | 6 main subtypes: Basal-like 1 Basal-like 2 Immunomodulatory Luminal androgen receptor Mesenchymal Mesenchymal stem-like | RNA expression | Basal-like 1 had a higher pathologic complete response rate after neoadjuvant chemotherapy and a better overall survival |
| Â | Â | Â | 4 main subtypes: Basal-like 1 Basal-like 2 Luminal androgen receptor Mesenchymal | Â | Â |
Burstein et al. [7] | 2015 | 198 | 4 main subtypes: Basal-like immune activated Basal-like immune suppressed Luminal androgen receptor Mesenchymal | RNA expression and DNA copy number | Four clinically distinct subtypes Survival outcomes were most favorable for basal-like immune activated and worst for basal-like immune suppressed |
Jiang et al.[6] | 2019 | 504 | 4 main subtypes: Immunomodulatory Basal-like immune suppressed Luminal androgen receptor Mesenchymal | RNA expression, DNA copy number and somatic mutations | Distinct patterns related to the Chinese TNBC population: higher frequencies of PIK3CA mutations and luminal androgen receptor subtype Basal-like immune suppressed with high-homologous recombination deficiency scores had a better prognosis when compared to those with low scores |
Bareche et al. [35] | 2018 | 550 | 5 main subtypes: Basal-like 1 Immunomodulatory Luminal androgen receptor Mesenchymal Mesenchymal stem-like | RNA expression, DNA copy number and somatic mutations | Immunomodulatory subtype was significantly associated with a better prognosis Luminal androgen receptor and mesenchymal stem-like subtypes were associated with low grade tumors |
Proteomic profiling | |||||
Gong et al. [76] | 2022 | 90 fresh- frozen | 4 main subtypes Immunomodulatory Basal-like immune suppressed Luminal androgen receptor Mesenchymal | Global proteomics and phospho-proteomics RNA expression, DNA copy number and somatic mutations | Four clinically distinct subtypes The proteome subtype that resembled immunomodulatory had the best survival while the proteome subtype that resembled luminal androgen receptor had the worst survival Potential therapeutic targets involved in fatty acid metabolism (e.g. FASN) specifically for the proteome subtype that resembled luminal androgen receptor A potential therapeutic target of NAE1 for the proteome subtype that resembled basal-like immune suppressed |
Asleh et al. [60] | 2022 | 88 Formalin- fixed paraffin- embedded | 4 main subtypes: Basal-like immune activated Basal-like immune suppressed Luminal androgen receptor Mesenchymal | Global proteomics | Four clinically distinct subtypes Survival outcomes were most favorable for the proteome subtype that resembled basal-like immune activated and worst for basal-like immune suppressed Potential therapeutic targets involved in antigen presentation (e.g., TAP1, HLA-DQA1) for the proteome subtype that resembled basal-like immune activated Potential therapeutic targets involved in fatty acid metabolism (e.g., FASN) for the proteome subtype that resembled luminal androgen receptor |